Holen Sie sich die Stockscreener-App
0.285
3.72%
-0.011
Handel nachbörslich:
.27
-0.015
-5.26%
Schlusskurs vom Vortag:
$0.296
Offen:
$0.2782
24-Stunden-Volumen:
7.36M
Relative Volume:
1.55
Marktkapitalisierung:
$3.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.26M
KGV:
-0.0334
EPS:
-8.54
Netto-Cashflow:
$-8.25M
1W Leistung:
-7.05%
1M Leistung:
-30.49%
6M Leistung:
-69.15%
1J Leistung:
-88.37%
1-Tages-Spanne:
$0.25
$0.2875
1-Wochen-Bereich:
$0.25
$0.6299
52-Wochen-Spanne:
$0.25
$4.00
Oragenics Inc Stock (OGEN) Company Profile
Firmenname
Oragenics Inc
Sektor
Branche
Telefon
813-286-7900
Adresse
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Vergleichen Sie OGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.285 | 3.91M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
There is no way Arrowhead Pharmaceuticals Inc (ARWR) can keep these numbers up - SETE News
Views of Wall Street’s Leading Experts on Oragenics Inc - SETE News
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, - GlobeNewswire
Power Nickel’s (TSX.V: PNPN) Hole Delivers “BIG”- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside! | FinancialContent Business Page - Financial Content
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
OGEN’s valuation metrics: A comprehensive analysis - US Post News
In the Green: Oragenics Inc (OGEN) Closes at 0.28, Up/Down -2.34 from Previous Day - The Dwinnex
Closing Bell Recap: Merck & Co Inc (MRK) Ends at 90.74, Reflecting a -9.07 Downturn - The Dwinnex
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex
Post-Trade Analysis: Charter Communications Inc (CHTR) Slides -0.36, Closing at 340.26 - The Dwinnex
US Stocks Mixed; Walt Disney Posts Upbeat Earnings - Benzinga India
United Micro Electronics ADR [UMC] Investment Guide: What You Need to Know - Knox Daily
Oragenics Inc (OGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
The Potential Rise in the Price of Dolby Laboratories Inc (DLB) following insiders activity - Knox Daily
Oragenics Inc Inc. (OGEN) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PCSO Lotto Results | February 5, 2025 - The Manila Times
Citigroup lifts StoneCo Ltd [STNE] price estimate. Who else is bullish? - The DBT News
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
Rubicon Technology (NASDAQ:RBCN) Now Covered by StockNews.com - Defense World
BlackRock Long-Term Municipal Advantage Trust (NYSE:BTA) Enters Standstill Agreement with Saba Capital Management, L.P.On January 20, 2025, BlackRock Long-Term Municipal Advantage Trust (NYSE:BTA) disclosed that it, along with BlackRock Advis - Defense World
Credit Suisse Group (NYSE:CS) Now Covered by StockNews.com - Defense World
Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World
Oragenics, Inc. Update: Janet Huffman Appointed Interim CEO - Defense World
Oragenics (OGEN) Stock Price, News & Analysis - MarketBeat
Oragenics gears up for Phase II trials, appoints new CEO By Investing.com - Investing.com Australia
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Ocean Power Technologies Demonstrates Multi-Day Advanced Remote Survey Capabilities - The Manila Times
Oragenics appoints interim CEO, ups CFO salary By Investing.com - Investing.com Canada
Oragenics appoints interim CEO, ups CFO salary - MSN
Oragenics Announces Leadership Changes and Relocation - TipRanks
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Energy Transfer Rocketed 42% in 2024 - The Globe and Mail
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
XOMA (NASDAQ:XOMA) and Oragenics (NYSE:OGEN) Head to Head Review - Defense World
Cencora Expands Specialty Leadership with $4.4 Billion Acquisition of Retina Consultants of America - MSN
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Anti-Oral Mucositis Drug Market 2025-2032: Revenue Growth, Business Opportunities, Trends and Forecast - WICZ
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics Simplifies Capital Structure and Advances Strategy - TipRanks
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - The Manila Times
Oragenics Strengthens Balance Sheet: $2.35M Preferred Share Conversion Streamlines Capital Structure - StockTitan
Oragenics director Alan Dunton sells $23 in common stock By Investing.com - Investing.com Canada
Oragenics director Alan Dunton sells $23 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock By Investing.com - Investing.com UK
Certain Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Oragenics announces termination of president's employment agreement By Investing.com - Investing.com South Africa
Oragenics announces termination of president's employment agreement - Investing.com India
Finanzdaten der Oragenics Inc-Aktie (OGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):